Other than ibrutinib, patients with M-CLL, devoid of TP53 aberrations and suit more than enough to tolerate FCR therapy, should be good candidates to the latter, With all the reward remaining that this procedure is often completed in 6 months even though ibrutinib must be taken indefinitely. This option could be significantly beneficial for non-com